In this video, Dr Marc S Sabatine addresses the context of the FOURIER-OLE long-term trial and how it impacts the current treatment paradigm. It also reports on what impact this extension study has on the guideline directed LDL-C targets and what this means for the use of PCSK-9 inhibitors.

This video is part of a series of interviews, recorded at ESC Congress 2022 in Barcelona, in which Dr Michelle L O’Donoghue, Dr Marc S Sabatine and Dr Robert P Giugliano consider the importance and implications of the FOURIER-OLE trial.

Watch next:

FOURIER-OLE: Implications for Real-World Practice

FOURIER-OLE: Long-term Safety of Evolocumab Therapy in Patients with Evident ASCVD

This programme is supported by an unrestricted educational grant from Amgen.